Medicinal Chemistry Research

, Volume 17, Issue 8, pp 507–514 | Cite as

Synthesis and pharmacological evaluation of 4-[2-hydroxy-3-(4-phenyl-piperazin-1-yl)-propoxy]-4-azatricyclo[,6]dec-8-ene-3,5-dione

  • Jerzy KossakowskiEmail author
  • Anna Bielenica
  • Marta Struga
  • Anna E. Koziol
Original Research


The synthesis and pharmacological activity of 4-[2-hydroxy-3-(4-phenyl-piperazin-1-yl)-propoxy]-4-aza-tricyclo[,6]dec-8-ene-3,5-dione is described. The structure of the compound was confirmed by elemental analysis, 1H nuclear magnetic resonance (NMR), 13C NMR, mass spectra, and X-ray crystallography. The compound exhibited significant affinity to both 5-HT1A and 5-HT2A receptors, similarly to aripiprazole, which is an atypical antipsychotic drug.


Cyclic imide derivative N-phenylpiperazine derivative 5HT1A and 5HT2A receptor affinity 


  1. Amlaiky N, Leclerc G, Carpy A (1982) Unusual reaction of N-hydroxyphthalimido ethers leading to oxygen-nitrogen heterocycles. J Org Chem 47:517–523CrossRefGoogle Scholar
  2. Boy KM, Dee M, Yevich J, Torrente J, Gao Q, Iben L, Stark A, Mattson RJ (2004) Ligand conformation has a definitive effect on 5-HT1A and serotonin reuptake affinity. Bioorg Med Chem Lett 14:4467–4470PubMedCrossRefGoogle Scholar
  3. Bristol-Myers Squibb Co. Instruction Sheet (2000)
  4. Cheng YC, Prusoff WH (1973) Relation between the inhibition constant Ki and the concentration of inhibitor which causes fifty per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108PubMedCrossRefGoogle Scholar
  5. Dockens RC, Salazar DE, Fulmor JE, Wehling M, Arnold ME, Croop R (2006) Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range. J Clin Pharmacol 46:1308–1312PubMedCrossRefGoogle Scholar
  6. Fiorino F, Perissutti E, Severino B, Santagada V, Cirillo D, Terracciano S, Massarelli P, Bruni G, Colavolli E, Renner C, Caliendo G (2005) New 5-Hydroxytryptamine1A receptor ligands containing a norbornene nucleus: synthesis and in vitro pharmacological evaluation. J Med Chem 48:5495–5503PubMedCrossRefGoogle Scholar
  7. Gentili D, Lapucci A, Macchia B, Macchia M, Martinelli A, Nencetti S, Orlandini E, Ferni G, Pinza M (1995) Synthesis and β-adrenergic activity of a series of 3-(substituted-benzylideneaminoxy)propanolamine derivatives. Farmaco 50:519–526PubMedGoogle Scholar
  8. Keck Jr PE, McElroy SL (2003) Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs 12:655–662PubMedCrossRefGoogle Scholar
  9. Kossakowski J, Wojciechowska A (2006) Synthesis of oxiran-2-ylmethyl and oxiran-2-ylmethoxy derivatives of some 4-azatricyclo[,6)]dec-8-ene-3,5-diones as potential beta-adrenolytics. Acta Pol Pharm 63:485–490PubMedGoogle Scholar
  10. Koziol AE, Chilmonczyk Z, Cybulski J (2006) Buspirone free base. Acta Cryst E62:o5616–o5618Google Scholar
  11. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA., Gonzalez AM, Silbey DR, Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612–627PubMedCrossRefGoogle Scholar
  12. Leysen JE, Niemegers CJE, Van Neuten JH, Laduron PM (1982) [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol 21:301–314PubMedGoogle Scholar
  13. Mattson RJ, Catt JD, Sloan CP, Gao Q, Carter RB, Gentile A, Mahle CD, Matos FF, McGovern R, VanderMaelen CP, Yocca FD (2003) Development of a presynaptic 5-HT1A antagonist. Bioorg Med Chem Lett 13:285–288PubMedCrossRefGoogle Scholar
  14. McGavin JK, Goa KL (2002) Aripiprazole. CNS Drugs 16:779–786PubMedCrossRefGoogle Scholar
  15. Middlemiss D, Blakeborough L, Leather SR (1977) Direct evidence for an interaction of beta-adrenergic blockers with the 5-HT receptor. Nature 267:289–290CrossRefGoogle Scholar
  16. Middlemiss DN, Fozard JR (1983) 8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur J Pharmacol 90:151–153PubMedCrossRefGoogle Scholar
  17. Sheldrick GM (1997) SHELXS97 and SHELXL97. University of Goettingen, GermanyGoogle Scholar
  18. Tandon M, O’Donnell MM, Porte A, Vensel D, Yang D, Palma R, Beresford A, Ashwell MA (2004) The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands. Bioorg Med Chem Lett 14:1709–1712PubMedCrossRefGoogle Scholar
  19. Tessler L, Goldberg I (2006) Crystal structures of aripiprazole, a new anti-psychotic drug, and of its inclusion compounds with methanol, ethanol and water. J Incl Phenomena Macrocycl Chem 55:255–261CrossRefGoogle Scholar

Copyright information

© Birkhäuser Boston 2008

Authors and Affiliations

  • Jerzy Kossakowski
    • 1
    Email author
  • Anna Bielenica
    • 1
  • Marta Struga
    • 1
  • Anna E. Koziol
    • 2
  1. 1.Department of Medical ChemistryThe Medical University of WarsawWarsawPoland
  2. 2.Faculty of ChemistryMaria Curie-Sklodowska UniversityLublinPoland

Personalised recommendations